Voyager Therapeutics (VYGR) Total Current Liabilities (2014 - 2026)

Voyager Therapeutics has disclosed Total Current Liabilities across 13 years of filings, most recently posting $16.7 million for Q2 2026.

• In Q2 2026, Total Current Liabilities fell 60.26% year-over-year to $16.7 million; the TTM figure through Jun 2026 stood at $16.7 million (down 60.26% YoY), while the FY2025 annual figure was $26.5 million, down 46.69% from the prior year.
• Total Current Liabilities came in at $16.7 million for Q2 2026 at Voyager Therapeutics, down from $17.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $101.7 million in Q1 2022 to a low of $16.7 million in Q2 2026.
• Average Total Current Liabilities over 5 years is $51.2 million, with a median of $44.8 million recorded in 2023.
• Year-over-year, Total Current Liabilities jumped 310.8% in 2022 and plunged 80.39% in 2023.
• Over 5 years, Total Current Liabilities stood at $72.6 million in 2022, then decreased by 11.13% to $64.5 million in 2023, then retreated by 22.82% to $49.8 million in 2024, then sank by 46.69% to $26.5 million in 2025, then tumbled by 37.13% to $16.7 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $16.7 million in Q2 2026, $17.5 million in Q1 2026, and $26.5 million in Q4 2025.